Skip to main content

Table 3 Overview of the demographic and clinical dataset

From: King’s Health Partners’ Prostate Cancer Biobank (KHP PCaBB)

Basics Sample Size 1796
Patients Consented 549
Number of variables 13
Involvement in clinical trial Yes /No
Demographics Demographics Age at diagnosis
Ethnicity
Postcode
Prostate Cancer Characteristics Diagnostic markers PSA
Gleason score
TNM stage
Treatment Treatment type Surgery, Active monitoring, Anti-cancer drug regimen (hormone therapy), Anti-cancer drug regimen (cytotoxic chemotherapy), Brachytherapy, Specialist palliative care
Comorbidities All, Previous/other cancers, Cardiovascular disease, HIV or infectious disease, Hyperlipidaemia and hypercholesterolemia, Diabetes, Psychological
Medication Total number of medications,
Erectile dysfunction medication
Outcome Disease stable, Discharged to GP, Treatment discharged to GP, Discharged to different hospital, Progression, Progression to metastasis, Recurrence, Death, Awaiting treatment, Refused further treatment, Treated privately, Lost to follow up
  1. The following abbreviations have been used: Prostate Specific Antigen (PSA), Human Immuno-Deficiency Virus (HIV) and General Practitioner (GP)